HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Nov.17) - 2023 NRDL Negotiation, Financing Data Won't Lie, Intco Medical

Joinn Laboratories (6127.HK) - Concerns Begin to Arise when the Monkeys Become More Expensive

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

Intco Medical Technology (300677.CH) - Declining Performance & Overcapacity Indicate Gloomy Outlook

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Intco Medical Technology  Lt / Equity Bottom-Up

<ul>
<li>NDRC issued "<em>Guiding Catalogue for Industrial Structure Adjustment</em>". The newly proposed adjustments deserve investors' attention, because they are the areas where investors could receive excess returns in China healthcare.</li>
<li>Obtaining assets from external sources remains paramount for MNCs. License-in mode isn’t outdated. As long as companies can make money, the ways to acquire assets can be diversified.</li>
<li>Intco's performance/stock price has bottomed out, and would gradually resume growth/rebound afterwards. Its market value would return to RMB20-30 billion. Intco would achieve a distress reversal, with attractive investment value.</li>
</ul>


NDRC issued "Guiding Catalogue for Industrial Structure Adjustment". The newly proposed adjustments deserve investors' attention, because they are the areas where investors could receive excess returns in China healthcare.
Obtaining assets from external sources remains paramount for MNCs. License-in mode isn’t outdated. As long as companies can make money, the ways to acquire assets can be diversified.
Intco's performance/stock price has bottomed out, and would gradually resume growth/rebound afterwards. Its market value would return to RMB20-30 billion. Intco would achieve a distress reversal, with attractive investment value.


China Healthcare Weekly (Jul.21) - New Growth Points by NDRC, License-In Model Isn’t Outdated, Intco